Sappiens

Sappiens is a French-Swiss clinical-stage biotechnology company focused on developing first-in-class, disease-modifying therapies for neurodegenerative disorders, specifically Parkinson's disease and amyotrophic lateral sclerosis (ALS). Spun out as a subsidiary of CXS Therapeutics, the company's lead candidate is CXS003, a patented, low-dose synergistic combination of two well-known antidiabetic drugs (metformin and glibenclamide). CXS003 is designed to simultaneously target three key drivers of neurodegeneration: oxidative stress, neuroinflammation, and mitochondrial dysfunction. By leveraging a drug repositioning strategy, Sappiens aims to accelerate clinical development and reduce safety risks, with plans to advance CXS003 directly into Phase 2 clinical trials.